



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8

In re Application of: :
Reich et al. : Confirmation No. 1285
Serial No. 10/759,878 : Group Art Unit: 1635
Filed: January 16, 2004 : Examiner: Not Assigned

For: COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF ICAM-1

Date Mailed: March 20, 2006


I HEREBY CERTIFY THAT THIS SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE VIA FIRST CLASS MAIL UNDER 37 CFR 1.8 AND IS ADDRESSED TO MAIL STOP AMENDMENT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450

Kathleen Pujol

(Typed or printed name of person mailing paper or fee)

(Signature of person mailing paper or fee)

Documents Mailed:
Information Disclosure Statement (2 pages)
Form PTO-1449 (1 page)
Cited References: (8)
Certificate of Mailing
Postcard



Attorney Docket No. 129402.00701

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

:

Reich et al.

:

Confirmation No. 1285

Serial No. 10/759,878

:

Group Art Unit: 1635

Filed: January 16, 2004

:

Examiner: Not Yet Assigned

For: COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF ICAM-1

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached form PTO-1449. It is respectfully requested that the documents be expressly considered and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

The undersigned asserts that each item of information contained in the information disclosure statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.



AUTHORIZATION

No fee is required. The Commissioner is hereby authorized to charge any additional fees which may be required for this submission, or credit any overpayment to Deposit Account No. 50-0436.

Respectfully submitted,

PEPPER HAMILTON LLP

Raymond A. Miller
Registration No. 42,891

Pepper Hamilton LLP
500 Grant Street, 50th Floor
Pittsburgh, PA 15219
Telephone: (412) 454-5000
Facsimile: (412) 281-0717
Date: March 20, 2006



Substitute form 1449 PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known			
				Application Number	10/759,878		
				Filing Date	January 16, 2004		
				First Named Inventor	Reich		
				Group Art Unit	1635		
Sheet 1 of 1				Examiner Name	Not Yet Assigned		
				Attorney Docket Number	129402.00701		
U.S. PATENT DOCUMENTS							
Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Number	Kind Code (if known)				
	AA	6,015,894		Bennet et al.	01-18-2000		
FOREIGN PATENT DOCUMENTS							
Examiner's Initials	Cite No.	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number Kind Code (if known)				
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
Examiner's Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or county where published.					T
	CA	KATZ et al., ICAM-1 Antisense Oligodeoxynucleotide Improves Islet Allograft Survival and Function, 2000, Cell Trans. 9:817-828					
	CB	DRAGUN et al., ICAM-1 antisense oligodesoxynucleotides prevent reperfusion injury and enhance immediate graft function in renal transplantation, 1998, Kidney Inter. 54:590-602					
	CC	ELBASHIR et al., Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells, 2001, Nature 411:494-498					
	CD	AGRAWAL et al., Antisense therapeutics: is it as simple as complementary base recognition?, 2000, Mol. Med. Today 6:72-81					
	CE	JEN et al., Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies, 2000, Stem Cells 18:307-319					
	CF	COBURN et al., siRNAs: a new wave of RNA-based therapeutics, 2003, J. Antimicrobial Chemotherapy 51:753-756					
	CG	CAPLEN, RNAi as a gene therapy approach, 2003, Expert Opin. Biol. Ther. 3(4):575-586					
	CH	AGAMI, RNAi and related mechanisms and their potential use for therapy, 2002, Curr. Op. Chem. Biol. 6:829-834					
Examiner Signature				Date Considered			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.